Esaxerenone (ESAX; Minnebro®, CS-3150, XL-560, Oklahoma, Japan), known to be a newly oral, non-steroidal selective blocker on the activity of mineralocorticoid receptor (MR), has been growingly used for the management of varying pathologic disorders, such as primary aldosteronism, refractory hypertension, chronic kidney disease, diabetic nephropathy, and heart failure [1,2,3,4,5,6,7,8,9,10]. This evidence concerns the gene NR3C2 and heart failure.